The study focuses on people with congenital hemophilia A, a rare condition in which the blood lacks a clotting protein called factor VIII, leading to bleeding problems. A frequent complication in these patients is synovitis, which means swelling and irritation of the thin tissue that lines a joint. The trial uses a medication named efanesoctocog alfa, administered by intravenous injection (a medicine delivered directly into a vein) to replace the missing clotting factor.
The purpose is to determine whether intensified replacement therapy can reduce or resolve signs of synovitis after a year of treatment. Participants receive regular doses of the medication for about 12 months, and during scheduled visits a trained specialist uses ultrasound (a painless scan that creates pictures of the joint with sound waves) to look at the thickness of the joint lining. This work is being done in a phase 3 clinical trial, which tests the treatment in a larger group to confirm its benefits and safety.
During the study, researchers record any side effects, measure how well the medicine prevents bleeding, and track the number of joint bleeds. Blood samples are taken to check factor levels, helping to evaluate both the effectiveness and safety of the treatment for this patient group.
Austria 
Germany 
